Literature DB >> 24176571

Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.

Scott Williams1, Edmund Chiong, Bannakij Lojanapiwat, Rainy Umbas, Hideyuki Akaza.   

Abstract

Many local and systemic options for prostate cancer have emerged in recent years, but existing management guidelines do not account for diversity in health resources between different countries. We present recommendations for the management of prostate cancer, stratified according to the extent of resource availability-based on a four-tier system of basic, limited, enhanced, and maximum resources-to enable applicability to Asian countries with differing levels of health-care resources. This statement of recommendations was formulated by a multidisciplinary panel from Asia-Pacific countries, at a consensus session on prostate cancer that was held as part of the 2013 Asian Oncology Summit in Bangkok, Thailand.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24176571     DOI: 10.1016/S1470-2045(13)70451-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  16 in total

1.  Ten-year outcomes of I¹²⁵ low-dose-rate brachytherapy for clinically localized prostate cancer: a single-institution experience in Japan.

Authors:  Narihiko Hayashi; Koji Izumi; Futoshi Sano; Yasuhide Miyoshi; Hiroji Uemura; Takeo Kasuya; Akiko Mukai; Masayuki Hata; Tomio Inoue
Journal:  World J Urol       Date:  2015-01-23       Impact factor: 4.226

2.  Evaluation of PSF1 as a prognostic biomarker for prostate cancer.

Authors:  H Tahara; H Naito; K Kise; T Wakabayashi; K Kamoi; K Okihara; A Yanagisawa; Y Nakai; N Nonomura; E Morii; T Miki; N Takakura
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-11-18       Impact factor: 5.554

Review 3.  Defining timeliness in care for patients with lung cancer: a scoping review.

Authors:  Adnan Ansar; Virginia Lewis; Christine Faye McDonald; Chaojie Liu; Muhammad Aziz Rahman
Journal:  BMJ Open       Date:  2022-04-07       Impact factor: 2.692

Review 4.  Influences of the Results from STRIVE Trial on the Combination Androgen Depletion Therapy for Advanced Prostate Cancer.

Authors:  Hideyuki Akaza
Journal:  Curr Urol Rep       Date:  2016-11       Impact factor: 3.092

5.  Oncological outcomes following robotic-assisted radical prostatectomy in a multiracial Asian population.

Authors:  Low Wei Xiang Alvin; Sim Hong Gee; Huang Hong Hong; Cheng Wai Sam Christopher; Ho Sien Sun Henry; Lau Kam On Weber; Tan Puay Hoon; Lee Lui Shiong
Journal:  J Robot Surg       Date:  2015-07-07

6.  Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects.

Authors:  Daniel Saltzstein; Neal D Shore; Judd W Moul; Franklin Chu; Raoul Concepcion; Stephan de la Motte; John A McLane; Stuart Atkinson; Alex Yang; E David Crawford
Journal:  Ther Adv Urol       Date:  2017-11-22

Review 7.  Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancer.

Authors:  Niels Eckstein; Bodo Haas
Journal:  Eur J Clin Pharmacol       Date:  2014-04-23       Impact factor: 2.953

8.  Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice.

Authors:  Bannakij Lojanapiwat; Wisan Anutrakulchai; Wilaiwan Chongruksut; Chaichawan Udomphot
Journal:  Prostate Int       Date:  2014-07-30

9.  Resveratrol directly targets DDX5 resulting in suppression of the mTORC1 pathway in prostate cancer.

Authors:  T Taniguchi; Y Iizumi; M Watanabe; M Masuda; M Morita; Y Aono; S Toriyama; M Oishi; W Goi; T Sakai
Journal:  Cell Death Dis       Date:  2016-05-05       Impact factor: 8.469

10.  Effect of gyromagnetic fields on human prostatic adenocarcinoma cells.

Authors:  Hongen Lei; Yongde Xu; Ruili Guan; Meng Li; Yu Hui; Zhezhu Gao; Bicheng Yang; Zhongcheng Xin
Journal:  Onco Targets Ther       Date:  2015-11-24       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.